Comparative Pharmacology
Head-to-head clinical analysis: DEXAMETHASONE versus MEDROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXAMETHASONE versus MEDROL.
DEXAMETHASONE vs MEDROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory cytokines (e.g., IL-1, IL-2, TNF-alpha). It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
4 to 48 mg orally once daily or every other day, depending on condition. Initial dose may be up to 48 mg/day.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Terminal half-life of methylprednisolone is 2.5-3.5 hours; for the active metabolite (prednisolone), half-life is 2.1-3.5 hours. Clinical context: Despite short half-life, pharmacodynamic effects persist beyond plasma presence due to receptor-mediated actions.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Renal (approximately 80-90% as metabolites, <5% unchanged); biliary/fecal (minor, <5%)
Category D/X
Category C
Corticosteroid
Corticosteroid